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Abstract
Background Glucagon-like peptide 2 (GLP-2), a nutri-
ent-responsive hormone, exerts various actions in the
gastrointestinal tract that are mediated by a G-protein
coupled receptor called GLP-2R. A little information is
available on GLP-2R expression in enteric neurons and
nothing on the interstitial cells of Cajal (ICC).
Methods We investigated presence and distribution of
the GLP-2R in the mouse duodenum by immunohis-
tochemistry and the potentialmotor effects ofGLP-2 on
the spontaneous and neurally evoked mechanical
activity.Key Results TheGLP-2Rwas expressed by the
myenteric and submucosal neurons. Labellingwas also
present in nerve varicosities within the circular mus-
cular layer and at the deep muscular plexus (DMP). No
immunoreactive nerve fiber was seen within the longi-
tudinal muscle layer. The GLP-2R-positive neurons
were either excitatory (SP- and choline-acetyltransfer-
ase-positive) or inhibitory (vasoactive intestinal poly-
peptide and nNOS-positive). The ICC, both at the
myenteric plexusandat theDMP,never expressedGLP-
2R but, especially those at the DMP, were surrounded
by GLP-2R-positive nerve varicosities co-expressing
either excitatory or inhibitory neurotransmitters.
Quantitative analysis demonstrated a consistent prev-
alence of GLP-2R on the excitatory pathways. In
agreement, the functional results showed that the
administration of GLP-2 in vitro caused decrease of
the spontaneous contractions mediated by nitric oxide
release and reduction of the evoked cholinergic
contractions. Conclusions & Inferences The present
findings indicate that the GLP-2R is expressed by
inhibitory and excitatory neurons, the GLP-2 inhibits
the muscle contractility likely decreasing cholinergic
neurotransmission and increasing nitric oxide pro-
duction, and this effect is possibly mediated by the
ICC-DMP recruitment.
Keywords enteric neurons, excitatory neurotrans-
mitters, glucagon-like hormones, immunohisto-
chemistry, inhibitory neurotransmitters, intestinal
motility.
INTRODUCTION
Glucagon- like peptide 2 (GLP-2), first recognized as an
intestinal growth factor,1 is a 33-amino-acid peptide
mainly produced by the enteroendocrine L-cells located
in the duodenum, distal small intestine, and colon.2,3
There are several evidences that GLP-2 inhibits gastro-
intestinal motility in laboratory mammals4–6 whereas
results from human studies are conflicting. In fact,
while Meier and co-workers7 showed that GLP-2 did
not influence gastric emptying, another study demon-
strated a dose-dependent increase in gastric emptying
time after GLP-2 infusion compared to controls.8
The GLP-2 effects are due to the interaction with a
specific receptor (GLP-2R) coupled to a G protein and
belonging to the class B glucagon-secretin receptor
family.9 GLP-2 binding to the transfected receptor
caused an increase in adenosine 3¢,5¢-cyclic monophos-
phate (cAMP) consistent with findings from studies of
related members of the glucagon/GLP-1R family.9,10
Furthermore, it has also been demonstrated that
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GLP-2R is coupled to different G protein subunits and
that it activates multiple signaling pathways.11,12
The presence of GLP-2R has been reported in the
central nervous system and in the gastrointestinal
tract.9,11,13–16 In particular, high levels of GLP-2R
mRNA have been found in the jejunum, followed by
duodenum, ileum, colon, and stomach9,17 and, by
immunocytochemical techniques, GLP-2R expression
was detected in subsets of human and mouse endocrine
cells of the stomach, and small,16 and large intestine.15
Guan and co-workers18 detected GLP-2R-immunoreac-
tivity (IR) in the enteroendocrine cells and myenteric
neurons of porcine jejunum where it co-localized with
serotonin in the former andwith endothelial nitric oxide
synthase (eNOS) and vasoactive intestinal polypeptide
(VIP) in the latter. Furthermore, by using in situ hybrid-
ization and immunohistochemistry, GLP-2Rwas found
on subepithelial myofibroblasts of rat, mouse, and
human small and large intestine,19 and in themyenteric
neurons of themouse jejunum and colon.20 We recently
showed the presence of GLP-2R-IR in neurons of myen-
teric and submucous plexus of mouse colon and dem-
onstrated thatmore than 50% of themyenteric neurons
shared the choline-acetyltransferase (ChAT)-IR.6 These
results, togetherwith the physiological ones, allowed us
to conclude that the activation of GLP-2R located on
cholinergic neurons modulated negatively the colonic
spontaneous and electrically evoked contractions
through inhibition of acetylcholine release.6
Information on the presence and cell localization of
the GLP-2R in the duodenum is lacking. Therefore, we
investigated, by immunohistochemistry, the cellular
distribution of GLP-2R in the mouse duodenum and
evaluated, by ChAT, SP, nNOS, and VIP co-labelling,
whether the enteric neurons expressing the GLP-2R
were excitatory, inhibitory or both. Besides, by using
the c-kit labelling, we also investigated whether the
interstitial cells of Cajal (ICC) express GLP-2R and/or
were innervated by GLP-2R-IR nerve fibers. In parallel,
the potential peripheral motor effects of GLP-2 on the
spontaneous mechanical activity and on neurally
evoked responses in mouse duodenum were examined
Results obtainedwouldhelp inunderstanding the role
of this receptor in one of the intestinal regions richer in
L-enteroendocrine cells and that it plays important roles
in the digestion and absorption processes.
MATERIALS AND METHODS
Animals and specimens collection
The experiments were authorized by Ministero della Sanita`
(Rome, Italy), following the guidelines of the European Commu-
nities Council Directive of 24 November 1986. Ten adult male
mice weighing 25 ± 1.5 g (C57BL/10, Harlan, Udine, Italy) were
fed ad libitum prior to use and then killed by cervical dislocation.
The abdomen was immediately opened and the duodenum was
removed from a position just distal to the pylorus. The content of
the excised segments was cleaned with 0.9% NaCl solution and
segments of about 2 cm in length were cut.
Immunohistochemistry
For the morphological experiments (four animals), the specimens
were fixed in 4% paraformaldehyde for 4 h at 4 C. The specimens
were cryoprotected in 30% sucrose in phosphate-buffered saline
(PBS) for approximately 12 h at 4 C and then frozen in Killik
cryostat-embedding medium (Bio-Optica, Milan, Italy) Transverse
cryosections, 8 lm thick, were cut and collected on polylysine-
coated slides and then stored at )20 C. The slices were pre-
incubated in 0.5% Triton (Sigma Aldrich, Milan, Italy) and 1.5%
bovine serum albumin (BSA) (Sigma Aldrich, Milan, Italy) in PBS
for 15 min at room temperature. And then the sections were
incubated with primary antibody diluted in 0.5% Triton and 1.5%
BSA in PBS for 24 h at 4 C and successively with secondary
antibody diluted in 0.5% Triton and 1.5% BSA in PBS for 2 h at
room temperature.
The GLP-2R antibody presently used recognizes the epitope
mapping within an N-terminal extracellular domain of GLP-2R of
human origin. Double labelling for GLP-2R/nNOS, GLP-2R/SP,
GLP-2R/c-kit, SP/nNOS, ChAT/SP, nNOS/ChAT, and nNOS/VIP
was performed as follows: after the first incubation as described
above, the sections were incubated again with another primary
antibody and with the specific secondary antibody. The double
labelling of GLP-2R with ChAT or with VIP gave unpredictable
results since there was a complete and unreliable overlapping in
some sections, while in others it did not. For this reason, we
decided to made the following experiments: transverse sequential
sections, 4 lm thick, were cryocut from each specimen and
collected on slides (four sections/slide; two slides/specimen) in
two separate areas, one area containing the first and the third
section, the other area containing the second and the fourth
section. Serial sections were placed on different slides. Each area
was bordered with a Pap Pen and the two sections of one area were
incubated with GLP-2R antibody as described above while the two
sections of the neighbor area were incubated with ChAT
polyclonal antibody (a generous gift of Dr. M. Schemann who
characterized this antibody,21 at final dilution of 1 : 500 overnight
at 4 C, or with VIP polyclonal antibody (Affinity Research
Products Limited, Nottingham, UK) at final dilution of 1 : 300
for 24 h at 4 C. The two immunoreactions were revealed with
the secondary antibodies Alexa Fluor 488 Donkey anti Goat and
the Alexa Fluor 568 Goat anti Rabbit (Invitrogen, San Diego, CA,
USA) 1 : 333, respectively, for 2 h at room temperature.
The antibodies details are reported in Table 1.
Specificity tests
For all the antibodies, negative controls were performed by
omitting the primary antibody or substituting it with a non-
immune rabbit, rat or mouse serum. For the monoclonal nNOS
antibody the sections were pretreated for 15 min with unlabelled
goat anti-mouse whole IgG molecule (Sigma, St.Louis, MO, USA).
To evaluate the specificity of the polyclonal GLP-2R antibody, the
staining was checked by pre-adsorption with its blocking peptide
(Santa Cruz Biotechnology, CA, USA). A mixture of GLP-2R
primary antibody, at working dilution, was combined with a
fivefold by weight excess of blocking peptide in a small volume of
L. Cinci et al. Neurogastroenterology and Motility
 2011 Blackwell Publishing Ltde384
phosphate buffer. This mixture was incubated overnight at 4 C;
then, centrifuged at 2000 g for 10 min. A small volume of
supernatant was used instead of the primary antibody in a usual
immunohistochemistry experimental procedure (Fig. 1D).
Quantitative analysis
The GLP-2R-IR neurons as well GLP-2R/nNOS, GLP-2R/SP,
ChAT/SP, nNOS/VIP, nNOS/ChAT, and nNOS/SP double
labelled neurons were counted on three sections cut at a distance
of 50 lm from each other, taken from the duodenum of three
control mice. Quantification of the neurons sharing GLP-2R-IR
and ChAT-IR or VIP-IR was done on the sequential sections
collected as described above. Digitized images of the entire
perimeter of the muscle wall were acquired using at x40 objective.
Field edges were defined based on structural details within the
tissue section to ensure that the fields did not overlap. Compar-
ison between pictures taken from GLP-2R-IR sections, from
ChAT-IR, and from VIP-IR sections at the same level was done to
identify and quantify those neurons that shared two markers. All
the counts were done by two of us blind to each others’ results on
a total of 12 sections for each antibody. The results were expressed
as mean ± SE of the number of neurons per 6 mm, i.e., the
perimeter of each section.
Physiology
For functional experiments, preparations were mounted in a
custom-designed horizontal organ bath (volume = 5 mL), which
was continuously perfused with oxygenated (95% O2 and 5%
CO2) and heated (37 C) Krebs solution with the following
composition (mmol L–1): NaCl 119; KCl 4.5; MgSO4 2.5; NaHCO3
25; KH2PO4 1.2; CaCl2 2.5; glucose 11.1. The mechanical activity
was recorded as previously described.22 Briefly, distal end of
duodenal segment was tied around the mouth of a J-tube, which
was connected via a T catheter to a pressure transducer (Statham
Mod. P23XL; Grass Medical Instruments, Quincy, MA, USA) and
to a syringe for filling the preparation with Krebs solution. The
legated proximal end was secured with a silk thread to an
isometric force transducer (Grass FT03; Grass Instruments Co.,
Quincy, MA, USA). Preparations were filled with 0.1 mL Krebs
solution and subjected to an initial tension of 0.1 g. Mechanical
signals were detected as changes in both endoluminal pressure
and isometric tension, which reflect the activity of circular and
longitudinal muscle, respectively,6,23 and recorded on an ink
writer polygraph (Grass model 7D; Grass Instruments Co.,
Quincy, MA, USA). Preparations were allowed to equilibrate for
about 60 min before starting the experiment. After the equilibra-
tion time, increasing concentrations of GLP-2 (1–100 nmol L–1)
were added non-cumulatively to the bath at and the effects on the
baseline tone and amplitude of phasic contractions were exam-
ined over a period of 10 min. The interval between single
concentrations was 40 min to avoid tachyphylaxis.
In another set of preparations, the influence of GLP-2
(1–100 nmol L–1) on the electrically evoked responses was evalu-
ated in the circular muscle. Electrical field stimulation (EFS) was
supplied by an S88 square-wave pulse generator (Grass Medical
Instruments, Quincy, MA, USA) and applied through a pair of
platinum plates, placed in parallel on either sides of the intestinal
segment. Trains of stimuli (duration 5 s, supramaximal voltage,
8 Hz and 0.5 ms pulse duration) were applied to duodenal
preparations at intervals of 70 s. Preliminary experiments were
performed to assess the neurotransmitters involved in the
responses. Under basal condition, EFS induced a muscular
contraction, which was abolished by atropine (1 lmol L–1), sug-
gesting its cholinergic origin. To study non-cholinergic non
adrenergic (NANC) responses, atropine (1 lmol L–1) and guaneth-
idine (1 lmol L–1) were added to Krebs solution at the beginning of
experiment. In NANC conditions EFS induced a transient relax-
ation followed by a NANC contraction. The relaxation was
abolished by L-NAME (300 lmol L–1), suggesting that it was
mediated by nitric oxide. The contraction was abolished by co-
administration of SR140333 (0.1 lmol L–1) and SR48968
(0.1 lmol L–1), NK1 and NK2 receptor antagonists, suggesting its
tachykinergic origin. All electrically evoked responses were
abolished by tetrodotoxin (TTX; 1 lmol L–1), suggesting their
neural origin.
Increasing concentrations of GLP-2 (1–100 nmol L–1) were left
in contact with the preparations for 7 min.
Data analysis and statistical tests The mean amplitude of the
spontaneous pressure waves was determined for 7 min before and
after GLP-2 administration. The changes in the mean amplitude
of the pressure waves induced by GLP-2 were expressed as per-
centages of the values obtained before GLP-2 addition to the bath.
The amplitude of the evoked-contractile response was measured
as the difference between the minimum of baseline activity and
the highest contraction following the EFS. Likewise the GLP-2
effects on the electrically evoked responses were expressed as a
percentage of the response produced by EFS in control conditions.
All data are expressed as mean values ± SEM. The letter n indi-
cates the number of experimental animals. Statistical analysis
was performed by means of ANOVA, followed by Bonferroni’s post
hoc test. A probability value of less than 0.05 was regarded as
significant.
Drugs The following drugs were used: atropine sulfate, guaneth-
idine monosulfate, Nx-nitro-L-arginine methyl ester (L-NAME),
tetrodotoxin (TTX) (Sigma-RBI, Milano, Italy), glucagon-like
peptide-2 (Tocris-Bioscience, Bristol, UK), ((S)1-{2-[3-(3,4-dichlor-
ophenyl)-1-(3-isopropoxy-phenylacetyl)- piperidin-3-yl]ethyl}-4-
Table 1 Primary and secondary antibodies used
Company Dilution
Primary antibodies
GLP-2R goat polyclonal Santa Cruz Biotechnology,
Santa Cruz, CA, USA
1 : 100
c-kit rabbit polyclonal Calbiochem, San Diego,
CA, USA
1 : 100
nNOS rabbit polyclonal Chemicon Millipore
Corporation, Billerica,
MA, USA
1 : 1000
nNOS mouse
monoclonal
BD Bioscience, Franklin
Lakes, NJ, USA
1 : 200
SP rat monoclonal Santa Cruz Biotechnology,
Santa Cruz, CA, USA
1 : 50
VIP rabbit polyclonal Affinity Research Products,
Nottingham. UK
1 : 300
Secondary antibodies
Alexa Fluor 488
Donkey anti Goat
Invitrogen, San Diego,
CA, USA
1 : 333
Alexa Fluor 488/568
Goat anti Rabbit
Invitrogen, San Diego,
CA, USA
1 : 333
Alexa Fluor 488/568
Goat anti-Mouse
Invitrogen, San Diego,
CA, USA
1 : 333
Alexa Fluor 568
Goat anti Rat
Invitrogen, San Diego,
CA, USA
1 : 333
GLP-2R, glucagon-like peptide 2 receptor; VIP, vasoactive intestinal
polypeptide.
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phenyl-1-azoniabicyclo[2.2.2]octane, chloride) (SR140333) and ((S)-
N-methyl-N[4-(4-acetylamino-4-phenylpiperi-dino)-2-(3,4-dichloro-
phenyl)butyl]benzamide (SR48968) (Sanofi Recherche, Montpel-
lier Cedex, France). Each compound was prepared as a stock
solution in distilled water. And SR48968 and SR140333 were
dissolved in dimethylsulphoxide (DMSO), which had no effect on
the tissue. The working solutions were prepared fresh the day of
the experiment by diluting the stock solutions in Krebs.
RESULTS
Immunohistochemistry
GLP-2R distribution Both myenteric and submucous
neurons expressed GLP-2R-IR (Fig. 1A,B). The labelling
was diffuse throughout the perikaryon and had a
granular aspect. Besides, several nerve fibers and end-
ings inside the ganglia were labelled and some of them
surrounded GLP-2R negative neurons. The GLP-2R-IR
fibers were also detected in the circular muscle layer
(Fig. 1A,B) and most of them were located at the deep
muscular plexus, DMP, (Fig. 1A,B). In the latter region
some of the positive nerve endings encircled thin,
spindle-shaped negative cells (Fig. 1B). No immunore-
active nerve fiber was seen within the longitudinal
muscle layer (Fig. 1A,B). As expected, GLP-2R-IR was
detected in some of the glandular cells located in the
epithelium and likely corresponding to the enteroen-
docrine ones (Fig. 1C).
Quantitative analysis demonstrated that the number
of GLP-2R-IR neurons/slice was 28.38 ± 0.8 in the
myenteric plexus (MP) and 1.4 ± 0.3 in the submucosal
plexus (SMP). Quantitative data are reported in detail
in the Table 2.
GLP-2R/c-kit double labelling The interstitial cells of
Cajal identified by c-kit-IR, both at the myenteric
plexus (ICC-MP) and at the deep muscular plexus
(ICC-DMP), never expressed GLP-2R-IR (Fig. 2A).
However, both of them were closely contacted by
GLP-2R-IR nerve varicosities (Fig. 2A) which fre-
quently co-expressed ChAT-IR, VIP-IR, nNOS-IR or
SP-IR (see below).
GLP-2R and neurotransmitter co-localizations At the
myenteric plexus, GLP-2R-IR was expressed by either
inhibitory (nNOS- and VIP-IR) (Fig. 2B and Fig. 2E,F,
respectively) or excitatory (SP- and ChAT-IR)
A
B
C D
Figure 1 (A and B) GLP-2R distribution. In
both myenteric (MP) and submucous (SMP)
neurons the labelling is diffuse throughout
the perikaryon and has a granular aspect.
Varicose nerve fibers are present at the MP,
within the circular muscle layer (CML) and
at the deep muscular plexus (DMP). No
immunoreactive nerve fibers are present
within the longitudinal muscle layer (LML).
In B, some of the positive DMP nerve end-
ings encircle thin, spindle-shaped negative
cells. (C) Two GLP-2R-IR enteroendocrine
cells (arrows) in the lining epithelium (E).
(D) undetectable GLP-2R-IR after pre-
adsorption with blocking peptide.
SM = submucosa. M = mucosa Scale Bar:
A-B-D = 30 lm, C = 10 lm.
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(Fig. 2C,D and Fig. 2G,H, respectively) neurons. In
addition, some of the nNOS-IR and SP-IR myenteric
neurons were contacted by GLP-2R-IR nerve endings
(Fig. 2B,C). At the SMP, only the SP-IR neurons
co-expressed GLP-2R (Fig. 2D). For details about the
number of neurons and the percentage of co-localiza-
tions see Table 2.
Neurotransmitters double labelling Several of the
ChAT-IR myenteric neurons shared SP-IR (Fig. 3A),
while in the SMP the two markers did not co-localized.
At the DMP (Fig. 3A) the two neurotransmitters
co-localized and the nerve endings closely contacting
negative cells (presumably, the ICC-DMP). None of the
ChAT-IR neurons, either at the MP or at the SMP
(Fig. 3B), co-expressed nNOS-IR. Many of the SP-IR
neurons were surrounded by nNOS-IR nerve endings at
both plexuses, but the two stainings never co-localized
(Fig. 3C). In the myenteric plexus some of the VIP-IR
neurons shared nNOS-IR (Fig. 3D), while in the sub-
mucous plexus these two markers did not co-localize.
Many of the DMP nerve fibers were nNOS/VIP-IR
(Fig. 3D) and in contact with the ICC-DMP (Fig. 3E).
For details about the number of the ChAT-, SP-,
nNOS-, and VIP-IR neurons and the percentage of those
sharing neurotransmitters co-localizations see Table 3.
Table 2 Mean number of GLP-2R-IR neurons/slice at the myenteric and submucous plexuses, and percentage of those co-expressing nNOS, VIP,
ChAT and SP. The slice measured 6 mm in perimeter
Plexus
Numbers
of the
GLP-2R-IR
neurons
% of those
co-expressing
nNOS-IR
% of those
co-expressing
VIP-IR
% of those
co-expressing
ChAT-IR
% of those
co-expressing
SP-IR
MP 28.4 ± 0.8 17.9 ± 2.0% 10.3 ± 1.5% 71.3 ± 5.8% 27.0 ± 1.4%
SMP 1.4 ± 0.3 0 0 0 100%
GLP-2R-IR, glucagon-like peptide 2 receptor immunoreactivity; VIP-IR, vasoactive intestinal polypeptide immunoreactivity; chAT-IR,
choline-acetyltransferase immunoreactivity.
A E
B F
C G
D H
Figure 2 (A) GLP-2R/c-kit double labelling.
The interstitial cells of Cajal (in red), both at
the myenteric plexus (MP) and at the deep
muscular plexus (DMP), are GLP-2R
negative, but contacted by many GLP-2R-IR
nerve varicosities (in green). (B) GLP-2R/
nNOS double labelling. At the myenteric
and submucous plexus (SMP) some neurons
(in yellow) co-express GLP-2R-IR (in green)
and nNOS-IR (in red). The same double
labelling is present in many intragangliar
and intramuscular nerve fibers, especially at
the deep muscular plexus. The arrow
indicates one myenteric nNOS-IR (in red)
neuron contacted by GLP-2R-IR (in green)
nerve endings. (C and D) GLP-2R/SP double
labelling. At the MP, two neurons (in
yellow) co-express GLP-2R-IR (in green) and
SP-IR (in red). The same double labelling is
present in the nerve fibers of the DMP that
surround negative spindle-shaped cells. In
(D) two submucous neurons, one double
labelled (in yellow) and one (in green)
GLP-2R positive only. (E and F) GLP-2R and
VIP labelling. Serial sections. At the MP, one
(1) of the two GLP-2R-IR neurons is also
VIP-IR (1). In F, One ICC at the DMP is
surrounded by many VIP-IR nerve endings.
(G and H) GLP-2R and ChAT labelling.
Serial sections. At the MP three (1,2,3) of the
GLP-2R-IR neurons are also ChAT-positive
(1,2,3). SM = sub mucosa. Scale Bar: 30 lm.
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Functional study
Effects of GLP-2 on spontaneous mechanical activity
As previously described,20 mouse duodenum exhibited
spontaneous mechanical activity characterized by
phasic changes in both endoluminal pressure
(1.5 ± 0.2 cm H2O, n = 6) and isometric tension
(175 ± 30 mg; n = 6). GLP-2 (1–100 nmol L–1) caused a
concentration-dependent inhibitory effect, character-
ized by a decrease of the spontaneous contraction
amplitude (Fig. 4) and a slight reduction of the basal
tone in the circular muscle, without affecting the
spontaneous mechanical activity of duodenal longitu-
dinal muscle (amplitude 170 ± 25 mg; n = 6 P > 0.05).
The GLP-2-induced inhibitory effects were not ob-
served in the presence of TTX (1 lmol L–1) or L-NAME
(300 lmol L–1), (Fig. 4).
Effects of GLP-2 on the neurally evoked mechanical
responses In normal Krebs, EFS (trains of 8 Hz for 5 s)
induced cholinergic contractions in the circular mus-
cle (2.6 ± 0.5 cm H2O; n = 6), which were reduced by
GLP-2 (1–100 nmol L–1) in a concentration-dependent
manner (Fig. 5A). The GLP-2 at the maximal concen-
tration tested (0.1 lmol L–1) produced about 60% of
reduction of the evoked contraction amplitude
(Fig. 5A).
In the presence of atropine (1 lmol L–1) and guanet-
idine (1 lmol L–1), EFS produced a transient nitrergic
relaxation of circular muscle (1.1 ± 0.4 cm H2O; n = 6),
followed by NANC contraction. (2.8 ± 0.6 cm H2O;
n = 6). GLP-2 (1–100 nmol L–1) induced a concentra-
tion-dependent increase of the relaxation amplitude
without affecting the NANC contraction (Fig. 5B).
DISCUSSION
The present immunohistochemical findings demon-
strated that in the mouse duodenum the neuronal cells
expressed the GLP-2R. The receptor was distributed in
the myenteric and submucous neurons and in several
nerve varicosities which were particularly abundant at
the DMP. Interestingly, about 30% of the GLP-2R-IR
neurons shared inhibitory neurotransmitters while up
to 70% were excitatory neurons. Finally, the GLP-2R-
IR nerve varicosities, surrounding the ICC at the MP
and at the DMP, co-expressed either inhibitory or
excitatory neurotransmitters. No GLP-2R-IR varicosity
was observed in the longitudinal muscle layer. Phys-
iological results demonstrated the ability of the GLP-2
to inhibit smooth muscle contraction by acting on
both excitatory cholinergic pathways and inhibitory
nitrergic pathways.
A
B
C
D
E
Figure 3 (A) Two of the 5 ChAT-IR myenteric neurons share SP-IR.
At the deep muscular plexus (DMP) the two markers co-localize
and the nerve endings surround negative cells (presumably the
interstitial cells of Cajal, ICC). (B) Neither the ChAT-IR neurons,
either at the myenteric plexus (MP) or at the submucous plexus (SMP),
nor the ChAT-IR nerve endings co-express nNOS-IR. (C) The SP-IR
neurons are surrounded by nNOS-IR nerve endings at both plexuses
but the two staining never co-localize. (D) In the MP one of the VIP-IR
neurons (asterisk) shares nNOS-IR. Many of the DMP nerve fibers
are nNOS/VIP-IR. (E) Numerous VIP-IR nerve endings (in red) are
in contact with the ICC-DMP (in green). SM = submucosa,
CML = circular muscle layer. Scale Bar: A-D = 30 lm, E = 10 lm.
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In a previous article we showed that in the mouse
colon more than 50% of the GLP-2R-IR myenteric
neurons were ChAT-positive and, in agreement with
the physiological results, we concluded that the
inhibitory action of the GLP-2 was due to a decrease
of acetylcholine release.6 On the basis of the present
data, the ability of the GLP-2 to inhibit duodenum
motility should be the result of more complex inter-
actions since the GLP-2R-IR is practically detected on
all types of neurons. Moreover, the functional findings
showing that the administration of GLP-2 in vitro
involved either the nitrergic or the cholinergic path-
ways suggest that the inhibition of the gastrointestinal
motor activity due to this peptide is the final result of a
double and likely opposite effect on the inhibitory and
excitatory neurons.
Co-localization experiments showed that up to 70%
of the GLP-2R-IR neurons shared ChAT-IR, therefore
the reduction in the evoked responses presently found
are likely imputable to the inhibition of Ach release,
similar to that observed in the mouse colon.6 Interest-
ingly, although the great majority of SP-IR neurons
co-expressed ChAT-IR, physiological results indicated
that the tachykinin-induced contractions were not
modified by the GLP-2 administration. This result
would suggest that those neurons sharing ChAT- and
GLP-2R-IR (the 52% out of the total cholinergic
neurons) represent a distinct population in respect to
those sharing ChAT- and SP-IR (the 37% out of the
total cholinergic neurons). However, since 47% out of
the SP-positive neurons were GLP-2R-IR and almost
85% of them were ChAT-positive it is very likely that
A
B C
Figure 4 (A) Original tracings showing the
effects of GLP-2 increasing concentrations
on the mechanical spontaneous activity of
the mouse duodenal circular muscle and the
absence of any influence in the presence of
L-NAME. Dotted line indicates the tone of
the preparation. (B) Concentration-response
curves for the inhibitory effects induced by
GLP-2 on the spontaneous contraction
amplitude before and after treatment of the
preparations with TTX (1 lmol L–1) or
L-NAME (300 lmol L–1). Data are expressed
as a percentage of the resting contraction
amplitude. (C) Concentration-response
curves for the inhibitory effects induced by
GLP-2 on the mechanical tone, which was
taken to be the difference between the
pressures observed before GLP-2 addition to
the bath and the new stable level reached in
the presence of each concentration of the
peptide. Each value is the mean ± SEM from
6 animals. *P < 0.05.
Table 3 Mean number of myenteric neurons/slice expressing nNOS, VIP, ChAT and SP and percentage of those co-expressing these molecules
and GLP-2R. The slice measured 6 mm in perimeter
nNOS-IR VIP-IR ChAT-IR SP-IR
Number of neurons 18.3 ± 1.4 10.0 ± 1.0 34.2 ± 2.2 17.0 ± 0.9
% of co-expressing GLP-2R-IR 27.3 ± 3.1% 34.8 ± 1.5% 51.9 ± 4.2% 47.8 ± 3.4%
% co-expressing nNOS-IR – 65.7 ± 3.4% 0 0
% co-expressing VIP-IR 29.3 ± 1.4% – 0 0
% co-expressing ChAT-IR 0 0 – 84.5 ± 1.5%
% co-expressing SP-IR 0 0 37.3 ± 1.7% –
GLP-2R-IR, glucagon-like peptide 2 receptor immunoreactivity; VIP-IR, vasoactive intestinal polypeptide immunoreactivity; chAT-IR, choline-
acetyltransferase immunoreactivity.
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SP-IR neurons that express GLP-2R represent part of
the GLP-2R/ChAT-IR. Therefore, on the basis of both
physiological and morphological results, we consider
that the interaction between the GLP-2 and its receptor
on the excitatory neurons selectively affects the
cholinergic neurotransmission without involving the
tachykinergic one. The possibility to differentially
regulate the release of these two neurotransmitters
from the same excitatory neuron was already
reported.24,25
We also presently showed that almost 20% of the
GLP-2R-IR neurons co-expressed nNOS while up to
27% out of the total nNOS-IR neurons shared the GLP-
2R-IR. The double labelling was detected either in the
soma or in the nerve endings located in the circular
muscle layer and, most of all, at the DMP. Comparing
these results with those obtained for the GLP-1R-IR
distribution in the mouse duodenum,22 similarities but
also significant differences emerge. Indeed, while the
co-expression of GLP-1R and nNOS was detected
within the myenteric plexus only,22 the GLP-2R/nNOS
co-labelling is also extended to nerve varicosities
located in the circular muscle layer and DMP. These
observations suggest that the GLP-1R is mainly located
on myenteric interneurons while GLP-2R is also
expressed by inhibitory motor neurons. The finding
that the majority of the GLP-2R-IR is detected on
cholinergic neurons (present data), while almost no
GLP-1R labelling was seen on this neuron type,20 is in
line with a different localization of these two receptors.
Moreover, on the basis of the physiological results, we
previously hypothesized that the GLP-1 exerts its
inhibitory action on smooth muscle indirectly by
activating nNOS-IR interneurons to produce NO,
which, in turn, inhibits the acetylcholine release by
the motor cholinergic ones.22 Presently, we have to
imagine a diverse mechanism of action for the GLP-2
to inhibit muscle contraction. Indeed, GLP-2 would act
directly on the nitrergic motor neurons increasing NO
production responsible for muscle relaxation. This
possibility fits well with the present physiological
findings showing that the inhibitory effect induced by
GLP-2 on spontaneous mechanical activity was
blocked by TTX or L-NAME and exogenous GLP-2
was able to increase the nitrergic relaxation caused by
EFS.
A B
Figure 5 Effects induced by GLP-2 increasing concentrations on the cholinergic contractions (A) or on NANC nitrergic relaxations and
tachychininergic contractions (B) in the circular muscle of mouse duodenum. Mechanical responses were evoked by EFS (train of 5 s, 0.5 ms,
supramaximal voltage, 8 Hz). Upper panel shows typical tracings and lower panel shows concentration-response curves. Data are expressed as
a percentage of the response obtained in the absence of GLP-2, considered 100%. Each value is mean ± SEM from six animals.
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In summary, our immunohistochemical and physi-
ological findings indicate that the GLP-2 can exert an
action on both excitatory and inhibitory neurons with
opposite effects, negatively modulating the former and
positively the latter ones. Different coupling between
GLP-2R and G proteins could explain these opposite
results. Indeed, a number of different cells transfected
with the GLP-2R have been used to examine GLP-2R
signaling. These studies have shown that GLP-2R
receptor can couple to alternative G proteins with
consequent increase or decrease in the cAMP intracel-
lular content11,12 and it is known that the increase in
cAMP facilitates neurotransmitter release while its
decrease inhibits this release.9,10,26 Moreover, it has
been reported that GLP-2R couples in a dose-dependent
manner to alternate G protein and cAMP accumula-
tion occurs at moderate concentrations (0.1–1 nmol
L–1), while cAMP reduction occurs at higher levels of
GLP-2.2,6,27 In addition, our previous study showed
that in mouse colon the inhibitory effects of GLP-2 on
evoked cholinergic contractions were significantly
inhibited by pertuxis toxin, a Gi/o protein inhibitor,
supporting the hypothesis that the GLP-2R may be
coupled to inhibitory G protein,6 while intestinal
muscle strips and fetal rat intestinal cells, all of which
express the endogenous GLP-2R, respond to GLP-2
treatment with an increase in cAMP.26–29 Therefore, it
might be supposed that in our preparation the GLP-2R
detected on inhibitory neurons binds to excitatory G
protein, while GLP-2R present on excitatory neurons
recruits inhibitory G protein.
A special consideration deserves the presence of
GLP-2R-IR nerve varicosities at the DMP. In fact,
whereas no ICC shared the GLP-2R-IR, the great
majority of the GLP-2R-IR inhibitory and excitatory
varicosities were found surrounding the ICC-DMP.
This ICC population is definitively recognized as the
main target of enteric neurotransmission playing an
intermediate role between the nervous system and the
circular smooth muscle cells. Therefore, it is very
likely that most of the GLP-2 mediated action needs
the ICC-DMP recruitment. In support of this hypoth-
esis there is the observation that exogenous GLP-2
failed to affect the mechanical activity of the longitu-
dinal smooth muscle and no GLP-2R-immunoreactive
nerve fiber was seen within the longitudinal muscle
layer.
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